Publications by authors named "C Astrua"
Introduction: Anorectal melanoma (ARM) is rare and highly lethal neoplasm. It has a poorer prognosis compared with cutaneous ones. Sentinel lymph node biopsy (SLNB) has become the preferred method of nodal staging method for cutaneous melanoma.
View Article and Find Full Text PDFPatients with treated solid tumors (TST) are a highly heterogeneous and difficult-to-treat population due to the risk of disease progression/recurrence or infection. We conducted an observational, retrospective, single-center study at the Dermatology Clinic of Turin with a focus on the special population of cancer patients with psoriasis treated with biologics. As of July 2023, 52 psoriatic patients with a prior/concomitant history of malignancy had taken biologic drugs.
View Article and Find Full Text PDFArticle Synopsis
- Recent advancements in stage III melanoma treatment focus on adjuvant therapies, leading to a decrease in completion lymph node dissection (CLND) procedures after positive sentinel node biopsy (SLNB).
- A study from the University of Turin compared relapse-free survival (RFS) and overall survival (OS) in 157 melanoma patients, finding no significant difference between those who underwent CLND and those who did not.
- The findings suggest that while CLND has minimal impact on RFS or OS, adjuvant therapies significantly lower the risk of relapse, highlighting their importance in treating melanoma patients.
This study was carried out at the Dermatologic Clinic of the University of Turin, Italy, to assess the effectiveness and safety of adjuvant therapy in patients who received either targeted therapy (TT: dabrafenib + trametinib) or immunotherapy (IT: nivolumab or pembrolizumab) for up to 12 months. A total of 163 patients participated, including 147 with stage III and 19 with stage IV with no evidence of disease. The primary outcomes were relapse-free survival (RFS), distant metastasis-free survival (DMFS), and overall survival (OS).
View Article and Find Full Text PDF